Glucoset

Glucoset is a Norwegian medical technology company founded in 2013 that is developing a minimally invasive, intravascular sensor for continuous blood glucose monitoring in intensive care unit (ICU) patients. The company originated as a spinout from the Norwegian University of Science and Technology (NTNU).

The core of Glucoset's technology is an optical fiber biosensor inserted through an existing indwelling arterial catheter, a common feature in ICU settings. This approach eliminates the need for new punctures or dedicated equipment. The sensor's tip contains a hydrogel that changes volume in response to varying glucose concentrations. An interferometric technique measures these changes, providing real-time, accurate blood glucose readings. This method is designed to be highly accurate, especially in the critical hypoglycemic range, and less susceptible to issues like coagulation or patient movement that can affect other monitoring solutions.

The primary market for Glucoset is hospitals, specifically ICUs, where precise and continuous glucose control is crucial for improving patient outcomes, reducing complications, and lowering costs. By providing a reliable stream of data, the system enables clinicians to maintain stable glucose levels and avoid dangerous fluctuations. The business model focuses on providing a disposable sensor that integrates easily into the existing clinical workflow. The company has received significant funding from various sources, including venture capital firms like Swiss Diabetes Venture Fund and grants from the European Innovation Council and the Research Council of Norway.

Keywords: continuous glucose monitoring, intravascular sensor, ICU, critical care, medical device, blood glucose monitoring, biosensor, optical fiber sensor, minimally invasive, hypoglycemia, medtech, hydrogel, arterial catheter, patient monitoring, glucose control, hospital technology, intensive care, spinout, venture capital, diabetes management